Astellas Pharma Inc: Renal Insufficiency, Chronic trials

The registry lists 27 Renal Insufficiency, Chronic studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 3Phase 2 5Phase 3 14Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin AlfaCompletedNCT02021318Phase 3Results posted
• Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring DialysisCompletedNCT01887600Phase 3Results posted
• A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney DiseaseActive, not recruitingNCT05970172Phase 3
• Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database AnalysisCompletedNCT05530291
• A Study to Evaluate the ePidemiology of anEmia Associated With chroNic Kidney Disease in Patients in Primary Care Using The Stockholm CREAtinine Measurement (SCREAM) RegisterCompletedNCT05015998
• Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on DialysisCompletedNCT04042350
• A Non-interventional, Epidemiological, Registry-based Evaluation of Anaemia in Swedish Patients With Chronic Kidney DiseaseCompletedNCT03643601
• A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With AnemiaCompletedNCT02988973Phase 3
• A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With AnemiaCompletedNCT02964936Phase 3
• A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With AnemiaCompletedNCT02952092Phase 3
• Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney DiseaseCompletedNCT02805348
• A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With AnemiaCompletedNCT02780726Phase 3
• A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With AnemiaCompletedNCT02780141Phase 3
• A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) TreatmentCompletedNCT02779764Phase 3
• Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With HyperphosphatemiaCompletedNCT02753894Phase 2
• Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in JapanCompletedNCT02510274Phase 1
• A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney DiseaseCompletedNCT02358096Phase 2
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney DiseaseCompletedNCT02218099Phase 1/2
• ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-CompletedNCT01964196Phase 2
• Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing HemodialysisCompletedNCT01872026Phase 1
• Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on DialysisCompletedNCT01742611Phase 3
• A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on DialysisCompletedNCT01742585Phase 3
• A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on HemodialysisCompletedNCT01057407Phase 3
• A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal DialysisCompletedNCT01017276Phase 3
• Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on HemodialysisCompletedNCT00892749Phase 3
• Study of Tacrolimus Immunosuppressive Therapy After Kidney TransplantationCompletedNCT00717379Phase 4
• A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on HemodialysisCompletedNCT00505037Phase 2